Skip to main content Skip to search Skip to main navigation
News: EMA

EMA: GCP-Guideline on Computerised Systems and Data Integrity

Last month, the EMA published the final guideline on computerised systems and data integrity in clinical trials, which will enter into force on 10 September 2023. Clinical trials are increasingly using computerised systems for data collection, which come with progressively more complex user surfaces.

The use of data collection tools is not mandatory but can improve and simplify many processes if used correctly. This includes a wide variety of functions to improve data completeness, consistency and unambiguity, e.g. automatic edit checks, automated data transfers, validation checks, assisting information and workflow control.

To ensure the quality and reliability of the examination data as well as the well-being and safety of the examinees the 52-page guideline outlines:

  • general definitions and principles of key concepts,
  • requirements for computerised systems, including validation, user management and the life cycle of electronic data; and
  • expectations for specific types of systems, processes and data.

The guideline also defines the new terminology ALCOA++. The ALCOA principle stands for data that must be accurate, legible, contemporaneous, original and attributable. The amendment refers to the traceability of the data throughout their lifecycle. Changes must be documented as part of the metadata. This ensures traceability and security, e.g. through an audit trail.

The guideline replaces the Reflection paper on expectations for electronic source data and data transcribed to electronic data collection tools in clinical trials from 2010.


Source:

EMA: Guideline on computerised systems and electronic data in clinical trials

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may Also be Interested in the Following Articles

FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

At the PDA/FDA Joint Regulatory Conference 2026, FDA made it clear that modern equipment alone does not ensure sterility assurance. The article examines GMP deficiencies identified during FDA inspections and the role of facility design in aseptic manufacturing.

Read more
Question of the Week | GMP-Verlag

How is Qualification Carried out in Accordance With the V-model Described in GAMP® 5?

Here's the answer:
Read more
News: Medical Devices

EMA: Harmonisation of Combination-Product Quality Assessment

EMA’s Combination Products Operational Group (COMBO) is working to improve alignment between notified body opinions (NBOps) and pharmaceutical quality assessment, according to its report on the meeting held on 8 October 2026.
Read more
PIC/S: Revision of the Framework for International Cooperation

PIC/S: Revision of the Framework for International Cooperation

PIC/S has revised the framework governing its international cooperation. The updated Pharmaceutical Inspection Co-operation Scheme, PIC/S 1/95 (Rev. 7), was adopted in Istanbul on 2 November 2026 and entered into force on the same day.
Read more
FDA Updates Framework for Coordinating Facility Evaluations and Inspections

FDA Updates Framework for Coordinating Facility Evaluations and Inspections

FDA has revised its framework for collaboration between the Center for Drug Evaluation and Research (CDER) and the Office of Inspections and Investigations (OII). Version 2.0 of the Concept of Operations (ConOps), effective October 21, 2026, supersedes the original June 2017 version.
Read more
Outsourced Activities in the GDP Environment Part III: Contract Giver and Contract Acceptor

Outsourced Activities in the GDP Environment Part III: Contract Giver and Contract Acceptor

For any outsourced GDP activity, there is a need for delimitation of responsibilities between a client (contract giver) and a contractor (contract acceptor). Read more about their roles and responsibilities in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
Previous
Next